Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GLENMARK.NSthis companyGlenmark Pharmaceuticals Limited	₹2,671.10	44.17×	5.72×	3.54×	21.53×	-44.3%	47.6%	23.5%	8.0%	13.0%	20.1%	3.2%	0.06×	-0.21×	19.16×	1.77×	0.2%	7	6.63	1	D+
AJANTPHARM.NSAjanta Pharma Limited	₹3,344.00	33.18×	7.74×	6.43×	22.46×	64.5%	51.4%	24.3%	19.4%	23.3%	20.5%	0.4%	0.06×	0.1×	82.23×	2.64×	1.0%	5	18.51	4	A
ALIVUS.NSAlivus Life Sciences Limited	₹1,474.40	21.18×	3.59×	4.69×	14.44×	-46.0%	44.6%	28.3%	22.1%	16.9%	15.6%	2.2%	0.02×	0.07×	134.39×	5.21×	0.5%	—	—	4	A-
ALKEM.NSAlkem Laboratories Limited	₹5,398.50	27.24×	4.54×	4.26×	18.9×	35.0%	65.4%	17.8%	15.6%	16.7%	12.5%	2.1%	0.15×	0.53×	16.32×	2.55×	1.0%	3	—	2	B-
AUROPHARMA.NSAurobindo Pharma Limited	₹1,855.30	21.62×	2×	2.25×	10.17×	130.3%	39.2%	15.1%	10.4%	9.2%	7.3%	3.7%	0.21×	-0.25×	13.22×	1.81×	0.3%	5	—	2	B-
CIPLA.NSCipla Limited	₹1,403.80	25.49×	2.87×	3.51×	15.19×	112.4%	42.7%	16.7%	13.8%	11.3%	9.8%	2.6%	0.02×	-0.06×	86.67×	3.44×	1.3%	4	9.92	4	A-
Peer median	—	25.49×	3.59×	4.26×	15.19×	64.5%	44.6%	17.8%	15.6%	16.7%	12.5%	2.2%	0.06×	0.07×	82.23×	2.64×	1.0%	5	14.22	4	—